AM Best Upgrades Credit Ratings of Somerset Reinsurance Ltd. and Somerset Reinsurance Company
The ratings of Somerset Re reflect the company's balance sheet strength, which AM Best assesses as very strong, as well as its adequate operating performance, neutral business profile and appropriate enterprise risk management (ERM).
The ratings of SRC reflect the company's balance sheet strength, which AM Best assesses as strong, as well as its adequate operating performance, neutral business profile and appropriate ERM.
Somerset Re and SRC are focused on providing reinsurance solutions for asset-intensive life insurance and annuity business, including programs for new business flow and management of legacy blocks of life insurance and annuities.
The rating upgrades reflect Somerset Re's ability to execute on its business plan, including positive core earnings trends in profitability and premium growth and also reflect SRC's support of the overall business plan.
Somerset Re's risk-adjusted capitalization, as measured by Best's Capital Adequacy Ratio (BCAR), is expected to remain at the strongest level. Liquidity is assessed as more than adequate to fund anticipated short-term obligations of the current blocks of business held on the company's balance sheet.
Furthermore, Somerset Re continues to enhance its position in its markets of operation as it continues to execute reinsurance agreements each year with known rated insurers in line with the company's business plan. Experience-related metrics are showing strong evidence of prudent pricing and investment management discipline.
AM Best anticipates capital infusions to continue that will support further new business growth over the intermediate term without the need to access additional funding.
The companies are backed by a very experienced reinsurance management team with deep ties to the industry. The ERM programs are well-developed and currently appropriate for the companies' business operations.
This press release relates to Credit Ratings that have been published on AM Best's website. For all rating information relating to the release and pertinent disclosures, including details of the office responsible for issuing each of the individual ratings referenced in this release, please see AM Best's Recent Rating Activity web page. For additional information regarding the use and limitations of Credit Rating opinions, please view Guide to Best's Credit Ratings. For information on the proper use of Best's Credit Ratings, Best's Performance Assessments, Best's Preliminary Credit Assessments and AM Best press releases, please view Guide to Proper Use of Best's Ratings & Assessments.
AM Best is a global credit rating agency, news publisher and data analytics provider specializing in the insurance industry. Headquartered in the United States, the company does business in over 100 countries with regional offices in London, Amsterdam, Dubai, Hong Kong, Singapore and Mexico City. For more information, visit www.ambest.com.
Copyright © 2025 by A.M. Best Rating Services, Inc. and/or its affiliates. ALL RIGHTS RESERVED.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250731809267/en/
Contacts
Stephen Vincent Associate Director +1 908 882 1705 stephen.vincent@ambest.com
Edward Kohlberg Director +1 908 882 1979 edward.kohlberg@ambest.com
Christopher Sharkey Associate Director, Public Relations +1 908 882 2310 christopher.sharkey@ambest.com
Al Slavin Senior Public Relations Specialist +1 908 882 2318 al.slavin@ambest.com
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Forbes
41 minutes ago
- Forbes
American Eagle Stock Surges After Trump Praises Sydney Sweeney For ‘Hottest' Ad
American Eagle stock skyrocketed Monday after President Donald Trump praised actress Sydney Sweeney for having the 'HOTTEST ad out there' amid a firestorm of controversy over an advertisement critics have accused of promoting eugenics, which some conservatives have instead hailed as a rebuke of 'wokeness.' President Donald Trump praised actress Sydney Sweeney's controversial American Eagle ad in a post on Monday. (Photo by Brendan SMIALOWSKI / AFP) (Photo by BRENDAN SMIALOWSKI/AFP via Getty Images) AFP via Getty Images American Eagle's stock price was up nearly 23% as of 3 p.m. EDT on Monday, a steep increase that started hours earlier, after Trump made a post on Truth Social praising a divisive commercial starring Sweeney the company debuted last week. Earlier Monday, Trump praised Sweeney's controversial marketing stint: 'It's for American Eagle, and the jeans are 'flying off the shelves.' Go get 'em Sydney!' Trump hailed Sweeney's apparent voter registration after multiple reports over the weekend indicated she is registered as a Republican voter in Florida. Trump compared Sweeney unfavorably to 'Woke singer Taylor Swift,' whom he previously said he 'hates' after the singer endorsed his election opponent Vice President Kamala Harris in October, calling her 'NO LONGER HOT.' In his post Monday, Trump cited the recent resignation of Jaguar CEO Adrian Mardell, who stepped down months after the British luxury vehicle company drew 'woke' allegations for a colorful and diverse rebrand, though the company said his resignation was unrelated to the controversy and had been planned. Trump said Jaguar should have learned from Bud Light, referencing the conservative-led boycotts against the beer company after it sent transgender influencer Dylan Mulvaney a customized beer can with her face on it in 2023. 'The tide has seriously turned — Being WOKE is for losers, being Republican is what you want to be. Thank you for your attention to this matter!' Trump said. In a marketing video for American Eagle, Sweeney dons a pair of the brand's jeans and a denim jacket and makes a pun on the words 'jeans' and 'genes.' 'Genes are passed down from parents to offspring, often determining traits like hair color, personality and even eye color. My jeans are blue,' Sweeney says, as the camera pans up to her face and reveals her blue eyes. The ad triggered backlash from critics on social media who felt the ad comes close to promoting eugenics, implying Sweeney's blonde-haired, blue-eyed genes are more desirable than other traits. Shalini Shankar, a Northwestern University anthropology professor who studies youth and advertising, told CNN she believes American Eagle was 'aligning themselves with a white nationalist, MAGA-friendly identity,' stating the company is 'trying to rebrand themselves for the present moment, and language is very deliberately used here.' How Have Sweeney And American Eagle Responded To The Controversy? Sweeney has not yet publicly addressed the controversy over her American Eagle ad. The company posted a statement over the weekend defending its marketing campaign: ''Sydney Sweeney Has Great Jeans' is and always was about the jeans. Her jeans. Her story. We'll continue to celebrate how everyone wears their AE jeans with confidence, their way. Great jeans look good on everyone.' A handful of high-profile Republicans have championed Sweeney's ad as a rebuke to 'woke' culture, including Vice President JD Vance, who backed the actress in an appearance on the conservative 'Ruthless' podcast over the weekend. 'My political advice to the Democrats is, continue to tell everybody who thinks Sydney Sweeney is attractive is a Nazi,' Vance said. In a post on X last week, Sen. Ted Cruz (R-Texas) wrote: 'Wow. Now the crazy Left has come out against beautiful women. I'm sure that will poll well….' White House communications director Steven Cheung slammed the backlash in a post on X last week, calling it 'cancel culture run amok' and 'warped, moronic, and dense liberal thinking.' Tangent Sweeney, who is best known for her roles in the HBO series 'Euphoria' and 'The White Lotus,' attended a screening of her upcoming film 'Americana' on Sunday night in Los Angeles. TMZ published footage of a heckler calling Sweeney's ad 'racist' as she arrived at the event. Further Reading What has America learned from the Sydney Sweeney situation? We asked the experts (CNN)
Yahoo
2 hours ago
- Yahoo
Fortifi Capital Surpasses $175 Million in Small Business Funding as It Marks Two-Year Anniversary
NEW YORK, August 04, 2025--(BUSINESS WIRE)--Fortifi Capital, a fast-growing provider of working capital solutions for small businesses, today announced it has surpassed $175 million in total funding deployed across the United States. The milestone coincides with the company's two-year anniversary, underscoring rapid growth and strong demand for flexible financing options among entrepreneurs. Founded in August 2023, Fortifi Capital has quickly become a trusted capital partner for small and mid-sized businesses seeking speed, transparency, and personalized service. With headquarters in New York and regional offices in White Plains, Garden City, and Somerset, NJ, the firm has supported thousands of businesses across a wide range of industries. As part of its growth strategy, Fortifi is investing in proprietary technology aimed at improving marketing, streamlining operations, and enhancing the customer experience. These initiatives will support continued scale while maintaining the company's high-touch service model. Fortifi Capital's leadership team brings over a decade of experience in the alternative finance space, combining deep industry expertise with a commitment to innovation. With $175 million deployed in just two years and a robust infrastructure in place, Fortifi Capital is positioned for continued expansion in the small business finance sector. About Fortifi Capital Fortifi Capital provides fast, flexible, and transparent working capital solutions to small businesses nationwide. Founded in 2023, the company has funded over $175 million to date and continues to invest in technology and service to meet the evolving needs of American entrepreneurs. Fortifi is headquartered in New York with regional offices in White Plains, Garden City, and Somerset, NJ. View source version on Contacts Media Contact: Gennadiy BelikovGennadiy@ (917)
Yahoo
2 hours ago
- Yahoo
INmune Bio's CaRe PC Trial of INKmune™ in Metastatic Castration-Resistant Prostate Cancer Meets Endpoints and Is Closed to Enrollment
BOCA RATON, FL, Aug. 04, 2025 (GLOBE NEWSWIRE) -- INmune Bio Inc. (NASDAQ: INMB) (the "Company"), a clinical-stage immunology and inflammation company, is pleased to report that its Phase I/II trial (the 'CaRe PC' trial) of INKmune™ for men with metastatic castration-resistant prostate cancer (mCRPC) has met its primary and secondary endpoints and is now closed to further enrollment. INKmune™ was well tolerated at all three dose levels in the trial, demonstrating an excellent safety profile, the primary endpoint of CaRe PC. Additionally, patients with low NK cell activation saw the greatest improvement in their biomarkers of NK cell activation, defining the target population for the next trials. 'INKmune was safe and effective at activating NK cells in a subset of more than half of these patients with advanced disease,' stated Dr. Mark Lowdell, CSO at INmune Bio. 'Excitingly we did see, in some patients, individual tumor lesions either reducing in size or completely disappearing during treatment, so we believe this could be evidence of a direct effect on tumor cell killing.' Following the successful completion of the Phase 1/2 trial of INKmune™ in patients with advanced-stage disease, INmune Bio plans to advance the program by designing a randomized Phase 2b trial in patients with less severe disease, enabling a more robust measurement of the drug's effects and potential clinical benefits. About INKmune™ INKmune™ is a pharmaceutical-grade, replication-incompetent human tumor cell line which conjugates to resting NK cells and delivers multiple, essential priming signals to convert the cancer patient's resting NK cells into tumor killing memory-like NK cells (mlNK cells). INKmune™ treatment converts the patient's own NK cells into mlNK cells. In patients, INKmune™ primed tumor killing NK cells have persisted for more than 100 days. These cells function in the hypoxic TME because due to upregulated nutrient receptors and mitochondrial survival proteins. INKmune™ is a patient friendly drug treatment that does not require pre-medication, conditioning or additional cytokine therapy to be given to the patients. INKmune™ is easily transported, stored and delivered to the patient by a simple intravenous infusion as an out-patient. INKmune™ is tumor agnostic; it can be used to treat many types of NK-resistant tumors including leukemia, lymphoma, myeloma, lung, ovarian, breast, renal and nasopharyngeal cancer. INKmune™ is treating patients in an open label Phase I/II trial in metastatic castration-resistant prostate cancer in the US this year. About INmune Bio Inc. INmune Bio Inc. is a publicly traded (NASDAQ: INMB), clinical-stage biotechnology company focused on developing treatments that target the innate immune system to fight disease. INmune Bio has three product platforms: the Dominant-Negative Tumor Necrosis Factor (DN-TNF) product platform utilizes dominant-negative technology to selectively neutralize soluble TNF, a key driver of innate immune dysfunction and a mechanistic driver of many diseases. DN-TNF product candidates are in clinical trials to determine if they can treat Mild Alzheimer's disease, Mild Cognitive Impairment and treatment-resistant depression (XPro™). The Natural Killer Cell Priming Platform includes INKmune® developed to prime a patient's NK cells to eliminate minimal residual disease in patients with cancer and is currently in a trial in metastatic castration-resistance prostate cancer. The third program, CORDStrom™, is a proprietary pooled, allogeneic, human umbilical cord-derived mesenchymal Stromal/Stem cell (hucMSCs) platform that recently completed a blinded randomized trial in recessive dystrophic epidermolysis bullosa. INmune Bio's product platforms utilize a precision medicine approach for diseases driven by chronic inflammation and cancer. To learn more, please visit Forward-Looking Statements Clinical trials are in early stages and there is no assurance that any specific outcome will be achieved. Any statements contained in this press release related to the development or commercialization of product candidates and other business and financial matters, including without limitation, trial results and data, including the results of the Phase 2 MINDFuL trial, the timing of key milestones, future plans or expectations for the treatment of XPro™, and the prospects for receiving regulatory approval or commercializing or selling any product or drug candidates may constitute forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. Any forward-looking statements contained herein are based on current expectations but are subject to several risks and uncertainties. Actual results and the timing of certain events and circumstances may differ materially from those described by the forward-looking statements because of these risks and uncertainties. CORDStrom™, XPro1595 (XPro™, pegipanermin), and INKmune®™ have either finished clinical trials, are still in clinical trials or are preparing to start clinical trials and have not been approved by the US Food and Drug Administration (FDA) or any regulatory body and there cannot be any assurance that they will be approved by the FDA or any regulatory body or that any specific results will be achieved. The factors that could cause actual future results to differ materially from current expectations include, but are not limited to, risks and uncertainties relating to the Company's ability to produce more drug for clinical trials; the availability of substantial additional funding for the Company to continue its operations and to conduct research and development, clinical studies and future product commercialization; and, the Company's business, research, product development, regulatory approval, marketing and distribution plans and strategies. These and other factors are identified and described in more detail in the Company's filings with the Securities and Exchange Commission, including the Company's Annual Report on Form 10-K, the Company's Quarterly Reports on Form 10-Q and the Company's Current Reports on Form 8-K. The Company assumes no obligation to update any forward-looking statements to reflect any event or circumstance that may arise after the date of this release. INmune Bio Contact: David Moss Co-founder and Chief Financial Officer (858) 964-3720 info@ Daniel Carlson Head of Investor Relations (415) 509-4590 dcarlson@ in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
